September 2016

PathoQuest partners with Charles River Laboratories

Friday, September 30, 2016

PathoQuest, a rapidly growing biotechnology company spun out from Institut Pasteur, has announced a preferred partnership with Charles River Laboratories, an early-stage CRO, to provide an improved Viral Safety Service offering to biopharmaceutical companies. While traditional molecular approaches to safety testing are limited to the identification of a limited, predefined list of viruses, the PathoQuest’s next generation sequencing (NGS) solution combines a proprietary curated virus database with an automated analysis pipeline. This provides a universal test for identifying viruses of any type in a single, comprehensive analysis that minimizes false negatives.

[Read More]

NCI collaborates with Multiple Myeloma Research Foundation

Friday, September 30, 2016

The National Cancer Institute (NCI) has announced a collaboration with the Multiple Myeloma Research Foundation (MMRF) to incorporate MMRF’s wealth of genomic and clinical data about the disease into the NCI Genomic Data Commons (GDC), a publicly available database that promotes the sharing of genomic and clinical data among researchers and facilitates precision medicine in oncology. The MMRF, located in Norwalk, Connecticut, is the first non-profit to donate information to the GDC, which will include data on more than 30,000 patients who have many other types of cancers by the end of the year. NCI is part of the NIH.

[Read More]

Amgen’s phase III migraine drug success

Friday, September 30, 2016

Amgen has announced positive top-line results for erenumab (AMG 334) from A phase III, RandomIzed, double-blind, placebo-controlled Study to Evaluate the efficacy and safety of erenumab in migraine prevention (ARISE). These data showed the ARISE study met the primary endpoint, demonstrating a statistically significant reduction from baseline in monthly migraine days in patients with episodic migraine treated with erenumab compared with placebo at 12 weeks. Erenumab is specifically designed to prevent migraine by blocking the Calcitonin Gene-Related Peptide (CGRP) receptor, which is believed to have a critical role in mediating the incapacitating pain of migraine.

[Read More]

INC Research and CISCRP name C2 winner of Inspiring Hope Ideathon

Thursday, September 29, 2016

INC Research Holdings, a global phase I to IV CRO, together with the Center for Information and Study on Clinical Research Participation (CISCRP), a nonprofit organization dedicated to engaging the public and patients as partners in the clinical research process, has announced Team “C2: The Clinical Study Change Agent Collective” was chosen as the winner of the 2016 “Inspiring Hope” Ideathon.

[Read More]

Barda grants $43.2 million to Sanofi Pasteur for Zika

Thursday, September 29, 2016

Sanofi and its vaccines global business unit Sanofi Pasteur have announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services has agreed to a proposal to fund the manufacture of an inactivated Zika vaccine for phase II development. Sanofi Pasteur committed to researching and developing a vaccine to prevent Zika in February, shortly after the World Health Organization declared an emergency.

[Read More]